Skip to content

Improvements in vitiligo repigmentation were maintained with Opzelura® over the long-term

Opzelura® is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.1

Woman looking forward smiling

Continued Opzelura® treatment for up to 2 years maintained high efficacy*2

Time to relapse in responders (Cohort A)2

Time to relapse in responders

Adapted from Harris JE, et al. 2023.2

Scroll right if necessary

Scroll horizontal icon

Cohort A (≥F-VASI90 at Week 52)2

  • 85% of patients maintained ≥F-VASI75 with continued Opzelura® treatment1,2
  • Almost twice as many patients relapsed after 1 year of withdrawal1,2
    • 75% (12/16) regained ≥F-VASI75 within a median time of 12 weeks after restarting Opzelura®
    • 69% (11/16) regained ≥F-VASI90 response within a median time of 15 weeks after restarting Opzelura®

Patients could still achieve near-complete repigmentation in their second year of Opzelura® treatment*†3

Time to response (Cohort B)3

Time to response

Adapted from Rosmarin D, et al. 2023.3

Scroll right if necessary

Scroll horizontal icon

Cohort B (<F-VASI90 at Week 52)3

  • 34% of patients who applied Opzelura® since Day 1 achieved F-VASI90 after an additional year of treatment3
  • 66% of patients who applied Opzelura® from Day 1 achieved F-VASI75 and 64% achieved T-VASI503

Opzelura® is contraindicated during pregnancy and breastfeeding.1

*Please note no statistical analysis was performed at 2 years.2,3

†5 patients were incorrectly assigned to Cohort B at LTE baseline.3

Abbreviations

F-VASI75, ≥75% reduction from baseline in Facial Vitiligo Area Scoring Index; F-VASI90, ≥90% reduction from baseline in Facial Vitiligo Area Scoring Index; LTE; long-term extension; T-VASI50, ≥50% reduction from baseline in Total Vitiligo Area Scoring Index.

References

  1. Opzelura® (ruxolitinib) cream Summary of Product Characteristics. Incyte Biosciences UK Ltd.
  2. Harris JE, et al. American Academy of Dermatology (AAD) Annual Meeting, March 17–21, 2023. Oral presentation.
  3. Rosmarin D, et al. American Academy of Dermatology (AAD) Annual Meeting, March 17–21, 2023. Oral presentation.

UNITED KINGDOM
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte by calling 00-800-0002-7423.

REPUBLIC OF IRELAND
Adverse events should be reported. Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie. Adverse events should also be reported to Incyte by calling 1800‑456‑748.